All cancer types, Breast cancer, Secondary cancers
Results
Phase 1/2
This trial looked at vistusertib and selumetinib for that had spread into the surrounding tissues or elsewhere in the body. Cancer that has spread is .
The trial was for people who didn’t have any options available to them.
It was open for people to join between 2015 and 2018. The team published some results in 2017 and reported some more results in 2022. Cancer Research UK supported this trial.
You pronounce selumetinib as sell-you-me-ti-nib.
Recruitment start: 8 June 2015
Recruitment end: 13 June 2018
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Peter Schmid
Cancer Research UK
AstraZeneca
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
Queen Mary University of London
This is Cancer Research UK trial number CRUKDE/14/010.
Last reviewed: 3 October 2024
CRUK internal database number: 12210
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
